Old Web
English
Sign In
Acemap
>
Paper
>
Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease
Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease
2019
Miriam B. Vos
Lara Dimick-Santos
Ruby Mehta
Stephanie O. Omokaro
Johannes Taminiau
Elmer Schabel
David E. Kleiner
Peter Szitanyi
Piotr Socha
Jeffrey B. Schwimmer
Stephanie Noviello
Debra G. Silberg
Richard Torstenson
Veronica Miller
Joel E. Lavine
Nathalie Adda
William Baldyga
Rajarshi Banerjee
Cynthia Behling
Sherif Boulos
Gary Burgess
Dania Calboli
Edgar Charles
Rose Christian
Claude Cohen-Bacrie
Doina Cosma-Roman
Claus-Peter Danzer
Ingrid Delaet
Mark H. DeLegge
Nicholas DiProspero
Kathleen Donohue
Laurent Fischer
Emer Fitzpatrick
Michael Fried
David Hagerty
Paula Hale
Keri Hildick
D Hum
Khurram Jamil
Lijuan Jiang
Saul J. Karpen
Matthew Kelly
Rohit Kohli
Kattayoun Kordy
Nancy Krieger
Joel E. Lavine
Lois Lee
Eric Lefebvre
Patricia López
Erica Lyons
Laura Malahias
S. Megnien
Peter Mesenbrink
Pansy Minnick
Christine Murray
Tien Nghiem
Nikki Nicholson
Wenjie Pang
Lisa Percival
Dan Peres
Margaret Powell
Dragos Roman
Mark Root
Claire Sampson
Arun J. Sanyal
Kathleen B. Schwarz
Star Seyedkazemi
David Shapiro
Reshma Shringarpure
Debra Silberg
Edward Smith
Robert H. Squires
William R. Treem
Pamela Vig
Miriam B. Vos
Mason Yamashita
Michael Zemel
Keywords:
Gastroenterology
General surgery
Nonalcoholic fatty liver disease
Internal medicine
Diabetes mellitus
Medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
55
References
8
Citations
NaN
KQI
[]